Related Experiment Video
Updated: Jun 6, 2026

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
Published on: May 25, 2022
Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers
Syoko Tanaka1, Kazuho Sakamoto, Masaya Yamamoto
1Department of Pharmacology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.
Abstract:
An adverse effect of statins, cholesterol-lowering drugs, is contractile dysfunction of skeletal muscles. We investigated the mechanism underlying this effect in cultured myofibers isolated from rats. Fluvastatin (Flv) for 72 h decreased caffeine- and ionomycin-induced contraction of myofibers and Ca(2+) release from sarcoplasmic reticulum (SR). Ca(2+)-shortening curves measured in skinned myofibers indicated that myofibrillar Ca(2+) sensitivity was unaffected by Flv. A luciferin-luciferase assay revealed less ATP contents in Flv-treated myofibers. Among mevalonate metabolites, including geranylgeranylpyrophosphate (GGPP), farnesylpyrophosphate (FPP), coenzyme Q9, and coenzyme Q10, only GGPP prevented Flv-induced ATP reduction. A selective Rab geranylgeranyltransferase (GG transferase) inhibitor, perillyl alcohol (POH), and a specific GG transferase-I inhibitor, GGTI-298, both mimicked Flv in decreasing ATP and contraction. Mitochondrial membrane potential was decreased by Flv, and this effect was rescued by GGPP and mimicked by POH and GGTI-298. An endoplasmic reticulum (ER)-to-Golgi traffic inhibitor, brefeldin A, and a Rho inhibitor, membrane permeable exoenzyme C3 transferase, both decreased ATP. We conclude that statin-induced contractile dysfunction is due to reduced Ca(2+) release from SR and reduced ATP levels in myofibers with damaged mitochondria. GGPP depletion and subsequent inactivation of Rab1, possibly along with Rho, may underlie the mitochondrial damage by Flv.
Insights
Statin drugs can impair skeletal muscle function by reducing cellular energy (ATP) and calcium release. This study reveals that geranylgeranylpyrophosphate (GGPP) depletion contributes to statin-induced muscle problems.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Statins are widely used cholesterol-lowering drugs.
- Skeletal muscle contractile dysfunction is a known adverse effect of statins.
Purpose of the Study:
- To investigate the cellular mechanisms underlying statin-induced skeletal muscle contractile dysfunction.
- To identify specific molecular pathways involved in statin toxicity.
Main Methods:
- Cultured rat myofibers were treated with fluvastatin (Flv).
- Measurements included muscle contraction, calcium (Ca2+) release from the sarcoplasmic reticulum (SR), myofibrillar Ca2+ sensitivity, and cellular ATP content.
- Effects of mevalonate metabolites and specific enzyme inhibitors (Rab geranylgeranyltransferase inhibitors) were assessed.
- Mitochondrial membrane potential was evaluated.
Main Results:
- Fluvastatin treatment reduced myofiber contraction and Ca2+ release from SR.
- ATP levels were decreased in Flv-treated myofibers, while myofibrillar Ca2+ sensitivity remained unaffected.
- Geranylgeranylpyrophosphate (GGPP) prevented Flv-induced ATP reduction and mitochondrial dysfunction.
- Inhibitors of Rab geranylgeranyltransferase mimicked Flv's effects on ATP and contraction.
- Fluvastatin decreased mitochondrial membrane potential, an effect reversed by GGPP.
Conclusions:
- Statin-induced muscle dysfunction stems from reduced Ca2+ release and ATP levels, linked to mitochondrial damage.
- GGPP depletion and subsequent Rab1 inactivation are implicated in statin-induced mitochondrial damage.
Related Concept Videos
Smooth Muscle Contraction
The onset of contraction is triggered by an increase in calcium ions within the sarcoplasm, similar to the process in striated muscle. However, smooth muscles have a relatively smaller reservoir of the sarcoplasmic...
The Role of Actin and Myosin in Non-muscle Cells
Actin and Myosin in Muscle Contraction
Cross-bridge Cycle
Muscle Contraction
Muscle Contraction

